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Rapport de synthèse 
Les troubles de la glycosylation (Congenital Disorders of Glycosylation, CDG) 
regroupent une famille de maladies multi-systémiques héréditaires causées par des 
défauts dans la synthèse de glycoconjugés. La glycosylation est une réaction enzymatique 
consistant à lier de façon covalente un glucide à une chaîne peptidique ou une protéine. Il 
existe deux types de glycosylation. La N-glycosylation est l'addition de glucides aux 
chaînes peptidiques en croissance dès leur entrée dans la lumière du réticulum 
endoplasmique. Elle s'effectue sur les futures glycoprotéines membranaires et conduit à 
des chaînes de sucres courtes et ramifiées. La 0-glycosylation est l'addition de glucides 
au niveau des résidus hydroxylés des acides aminés sérine et thréonine des chaînes 
peptidiques déjà présentes dans la lumière de l'appareil de Golgi. Elle est, dans la plupart 
des cas, effectuée sur les protéoglycanes et conduit à des chaînes de sucres longues et non 
ramifiées. La classification des CDG repose sur le niveau de l'étape limitante de la 
glycosylation. Les CDG de type 1, plus fréquents, regroupent les déficits enzymatiques se 
situant en amont du transfert de I 'oligosaccharide sur la chaîne peptidique. Les CDG de 
type 2 regroupent ceux ayant lieu en aval de ce transfert. Parmi les nombreux différents 
sous-types de CDG, le CDG de type ld est causé par une anomalie de la 
mannosyltransferase, enzyme codée par le gène ALG3 (chromosome 3q27). Jusqu'à ce 
jour, six patients atteints de CDG ld ont été reportés dans la littérature. Notre travail a 
permis de décrire un septième patient et d'affiner les caractéristiques cliniques, 
biologiques, neuroradiologiques et moléculaires du CDG Id. Notre patient est notamment 
porteur d'une nouvelle mutation de type missense sur le gène ALG3. Tous les patients 
atteints de CDG ld présentent une encéphalopathie progressive avec microcéphalie, 
retard psychomoteur sévère et épilepsie. Une ostéopénie marquée est présente chez 
certains patients. Elle est parfois sous diagnostiquée et révélée uniquement lors de 
fracture pathologique. Les patients atteints de CDG ld présentent également des traits 
dysmorphiques typiques, mais aucune atteinte multi-systémique ou anomalie biologique 
spécifique n'est retrouvée telle que dans les autres types de CDG. Le dépistage 
biochimique des troubles de la glycosylation se fait par une analyse simple et peu 
coûteuse qui est l'analyse de la transferrine sérique par isoelectrofocusing ou par 
électrophorèse capillaire. Un tel dépistage devrait être effectué chez tout patient 
présentant une encéphalopathie d'origine indéterminée, et cela même en l'absence 
d'atteinte multi- systémique. Notre travail a été publié sous forme d'article de type 
« short report», peer-reviewed, dans le Journal of Inherited Metabolic Diseases. Le 
Journal est une révue spécialisée du domaine des erreirs innées du métabolisme. 
S'agissant d'un seul patient rapporté, l'article ne montre que très synthétiquement le 
travail effectué, Pour cette raison un complément à l'article avec matériel, méthodes et 
résultats figure ci-après et concerne la partie de recherche moléculaire de notre travail. La 
doctorante a non seulement encadré personnellement le patient au niveau clinique et 
biochimique, mais a plus particulièrement mis au point l'analyse moléculaire du gène 
ALG3 dans le laboratoire de Pédiatrie Moléculaire pour la première fois ; cela a impliqué 
l'étude du gène, le choix des oligonucleotides et l'optimisation des réactions 
d'amplification et séquençage. 
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Smnmary Congenital disorders of glycosylation (CDG) 
are a family of mul tisystem inheri ted disorders caused by 
defects in the biosynthesis of N- or 0-glycans. Among 
the many different subtypes of CDG, the defect of a 
mannosyltransferase encoded by the humanALG3 gene 
(chromosome 3q27) is known to cause CDG Id. Six 
patients with CDG Id have been described in the litera-
ture so far. We further delineate the clinical, biochemi-
cal, neuroradiological and molecular features of CDG 
Id by reporting an additional patient bearing a navel 
missense mutation in the ALG3 gene. AU patients with 
CDG Id display a slowly progressive encephalopathy 
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with microcephaly, severe psychomotor retardation and 
epileptic seizures. They also share some typical dysmor-
phie features but they do not present the multisystem 
involvement observed in other CDG syndromes or any 
biological marker abnormalities. Unusually marked 
osteopenia is a feature in some patients and may re-
main undiagnosed until revealed by pathological frac-
tures. Serum transferrin screening for CDG should be 
extended to all patients with encephalopathy ofunknown 
origin, even in the absence of multisystem involvement. 
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Introduction 
Congenital disorders of glycosylation (CDG) are a 
family of heterogeneous multisystem inherited disorders 
caused by defects in the biosynthesis of glycoconjugates, 
affecting N- or 0-glycosylation. N-Glycosylation of pro-
teins starts in the endoplasmic reticulum, where different 
enzymes synthesize oligosaccharide chains linked to a 
membrane-bound lipid support (dolichol); these chains 
are then transferred to proteins. The process continues 
in the Golgi apparatus, where protein-bound glycans 
undergo remodelling and processing with addition and/ 
or excision of individual sugars. Defects that alter the 
stepwise assembly of the lipid-linked oligosaccharide 
(LLO: Glc3Man9GlcNAc2) or its transfer to proteins 
within the endoplasmic reticulum are called CDG type I. 
In this group of defects, proteins lack entire sugar chains 
(glycans); this results in changes in protein folding, 
stability and turnover. Defects in the remodelling of 
protein-bound glycans in the Golgi are called CDG type 
II (Marquardt and Denecke 2003). Both isoelectric 
focusing and capillary electrophoresis of serum trans-
ferrin are sensitive screening methods to detect the two 
Fig. 1 Brain MRI of the 
patient at age 4 months 
(a) and 15 months 
(b, c and d). (a) Enlargement 
of subarachnoid spaces and 
plagiocephalic deformation 
of the skull in an axial 
Tl-weighed image;(b) cortical 
atrophy with no abnormal 
gyration in an axial 
Tl-weighed image;(c) 
white-matter atrophy 
in an axial T2-weighed image; 
(d) atrophy of the brainstem 
and vermis and thin corpus 
callosum in a sagittal 
Tl-weighed image 
~ Springer 
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patterns of CDG glycosylation anomaly, pointing to a 
defect in one of the two parts of the pathway. Today, at 
least 16 different subtypes of N-glycosylation defects 
are known (Marquardt and Denecke 2003; Jaeken 
and Matthijs 2007; Grünewald 2007; Vodopiutz and 
Bodamer 2008). Although the clinical diversity of CDG 
is remarkable, even within each group, most subtypes 
are characterized by a multisystem involvement with 
abnormalities in several biological markers. 
Mutations in the human ALG3 gene (chromosome 
3q27), coding for the first dol-P-Man-dependent man-
nosyltransferase, were recognized as the molecular 
defect causing CDG type Id (OMIM #601110) (Korner 
et al 1999) in the first index patient described by Stibler 
(Stibler et al 1995). The resulting defect leads to accumu-
lation of the LLO intennediate dol-PP-GlcNAc2Man5. 
N-Glycosylation is abnormal owing to the transfer of 
truncated LLOs and to the incomplete utilization of 
N-glycosylation sites. Six patients with CDG Id 
(formerly named CDG type IV) have been reported so 
far (Denecke et al 2004, 2005; Korner et al 1999; Kranz 
et al 2007; Schollen et al 2005; Sun et al 2005). Constant 
clinical features are severe epilepsy, microcephaly, visual 
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impairment due to optic atrophy, and severely delayed 
psychomotor development. 
We report a seventh patient with molecularly 
confirmed CDG Id in order to further delineate the 
clinical, biochemical and radiological features of this 
disease. 
Case report 
Our patient is the third child of healthy non-
consanguineous parents of Swiss and Italian origin. 
The family history is unremarkable. Pregnancy and 
delivery were uneventful. He was born at term with a 
weight of 3790g (>90th centile), a length of 50 cm 
(50th-90th centile) and a head circumference of 34 cm 
(50th centile). The neonatal period was uneventful. 
Epileptic seizures with hypotonia, tonic-clonic move-
ments of the limbs, and eye revulsion started at 
4 months and responded initially to benzodiazepines 
and phenobarbital. The child presented several dys-
morphie features such as microcephaly, triangular face 
with retrognathism, hypertelorism, large low-implanted 
Fig. 2 Phenotypic features of 
the patient at age 5 years: 
microcephaly, large and 
low-set ears, broad and fiat 
nasal bridge, thin upper lip, 
triangular mouth, long and 
thin fingers, adducted 
thumbs 
ears, widened nasal bridge, adducted thumbs and long, 
thin fingers. There was bilateral cryptorchidism. He did 
not present inverted nipples, abnormal subcutaneous 
fat tissue distribution, heart anomalies or hepatic dys-
function as seen in other patients with CDG syndromes. 
Brain MRI performed at 4 months revealed enlarged 
subarachnoid spaces and cranial asymmetry (Fig. la). 
Spectroscopy revealed a discrete lactate elevation 
within the white matter in the frontal area. The EEG 
showed very frequent discharges (every 30s) from 
hi-occipital and hi-temporal focuses, corresponding to 
clinical episodes of gaze deviations upwards and 
towards the left, followed by rotatory eye movements 
and closure. These episodes lasted 6-7s, frequently 
accompanied by respiratory pauses. Clinical seizures 
and EEG improved under valproate treatment. 
At 15 months the patient showed severe growth and 
psychomotor retardation. Epilepsy was reasonably 
controlled by valproate, with some rare epileptic 
seizures triggered by fever. Neurological examination 
showed severe axial hypotonia and spastic tetraparesis. 
He was unable to sit, to hold his head, and to open his 
hands, which were permanently fisted. He could hold 
5 if:! Springer 
objects and bring them to his mouth, but he could not 
transfer them from one hand to the other. Visual con-
tact was poor and developmental age was estimated at a 
level of 4 months. The clinical course was marked by 
repetitive ear and pulmonary infections as well as 
gastro-oesophageal reflux. Brain MRI at 15 months of 
age (Fig. lb, c, d) showed diffuse cortico-subcortical 
atrophy, progression of white-matter atrophy and mild 
atrophy of the vermis. Ophthalmological examination 
showed a latent nystagmus triggered by occlusion; 
funduscopy revealed hypopigmentation of the retina 
and optic atrophy. Abdominal ultrasound was normal, 
except for left pyelo-caliceal dilatation without reflux. 
No heart anomaly was found on echocardiography. 
Metabolic investigations (amino acids, urinary 
organic acids, ammonia, lactate, blood pH, very long-
chain fatty acids) were normal. Capillary electropho-
resis analysis of serum transferrin showed a type 1 
pattern with increased asialo- and disialotransferrin 
and presence of tetrasialotransferrin. CDG type la and 
lb were excluded by enzymatic analysis in leukocytes. 
JIMD Short Report #118 (2008) Online 
Biochemical analysis of dolichol-oligosaccharides and 
protein-linked oligosaccharides in fibroblasts revealed 
accumulation of truncated Man5-GlcNAc2 oligosaccha-
ride in addition to the mature Glc3Man9GlcNAc2 oligo-
saccharide; this feature is typical of CDG type Id. 
Mutation analysis of the ALG3 gene in both the 
cDNA and genomic DNA showed two compound 
heterozygous mutations, one in exon 1 [c.116C>T, 
p.P39L] and the other in exon 4 [c.512G>A, p.R171Q]. 
Sequencing of exons 1 and 4 of the ALG3 gene in both 
parents confirmed segregation (maternai mutation 
p.P39L, paternal mutation p.Rl 71 Q). The two nucle-
otide changes found in our patient were not present in 
100 chromosomes of anonymous unrelated European 
controls. 
The patient is at present 5 years old, his weight 
follows the 3rd centile, bis length follows the 25th 
centile and his head circumference is far below the 3rd 
centile (44 cm). His dysmorphie features are shown in 
Fig. 2. He is fed a diversified blended oral diet, with 
increasing difficulties due to his gastro-oesophageal 
Tablel Clinical and biochemical findings in our patient and ail other CDG Id patients described so far (modified from Kranz et al 
2007) 
Source This Kranz et al Kranz et al Sun et al 
article (2007) (2007) (2005) 
Sex 
Dysmorphie features 
Strabismus 
Facial dysmorphisms 
Inverted nipples 
Subcutaneous fat pads 
Limb abnonnalities 
Neurological features 
Hypo-/hypertonia 
Seizures 
Visual Impainnent 
Cerebellar/cerebral 
hypoplasia 
Psychomotor retardation 
Li ver/intestine/ endocrine 
Hepatic fibrosis/cirrhosis 
H ypoalbuminemia 
Coagulopathy 
Protein-losing 
enteropathy 
H yperinsulinaemic 
hypoglycaemia 
Food Intolerance 
M 
++ 
+ 
++ 
++ 
++ 
+ 
++ 
Skeletal manifestations 
Osteopenia/pathological + 
fracture 
F 
++ 
+ 
+ 
+ 
++ 
+ 
+ 
+ 
++ 
+ 
++ 
M 
+ 
+ 
+ 
++ 
++ 
++ 
++ 
++ 
++ 
+ 
+ 
F 
n.k. 
++ 
+ 
+ 
+ 
+ 
+ 
+ 
n.k. <lied 
tao young 
+ 
+ 
+ 
n.k. 
+ 
n.k. 
n.k. 
++, very severe; +, symptom present; -, symptom absent; n.k., not known. 
~ Springer 
Schollen et al J. Denecke, persona! Stibler et al (1995) 
(2005) communication Ki:irner et al (1999) 
F 
n.k. 
+ 
n.k. 
n.k. 
+ 
+ 
++ 
+ 
+ 
+ 
n.k. 
n.k. 
n.k. 
n.k. 
n.k. 
n.k. 
n.k. 
M 
+ 
+ 
n.k. 
n.k. 
+ 
+ 
+ 
+ 
+ 
+ 
n.k. 
n.k. 
M 
n.k. 
+ 
+ 
+ 
+ 
+ 
+ 
n.k. 
n.k. 
n.k. 
n.k. 
n.k. 
n.k. 
n.k. 
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reflux. He attends a special needs school and is pre-
scribed weekly physiotherapy, occupational therapy as 
well as assistive devices to improve muscle tone and 
comfort. Axial hypotonia remains very severe, with 
development of kyphoscoliosis. His movement pattern 
is abnormal, with continuous involuntary movements 
of the head and the upper limbs. Visual fixation is 
disturbed by the continuous head movement and, 
although the child seems to recognize familiar faces, 
there is no real visual contact. Communication is 
limited to undifferentiated vocalization with a better 
response to auditory than to visual stimulation. A 
pathological fracture of the right humerus recently 
occurred during the transfer between two caretakers. 
Radiological examination revealed severe osteopenia 
without specific bone changes; no shortened long bones 
or hypoplastic vertebral bodies and ribs were noted as 
reported in other CDG syndromes. Bone density mea-
sured on the lumbar spine showed a Z-score of -3.9 SD. 
Several biochemical parameters of multisystem func-
tions were normal at follow-up from 15 months to 
5 years, including liver function tests (transaminases, 
coagulation tests, plasma albumin), glomerular and 
tubular renal function tests (plasma urea and creati-
nine, tubular reabsorption of glucose, electrolytes and 
amino acids), muscle enzymes (creatine kinase), nutri-
tional parameters, thyroid hormones, insulin/glucose 
ratios, calcium-phosphate metabolism and parathyroid 
hormone. 
Discussion 
On the basis of the clinical features of our patient and 
of the published data of the six known patients with 
CDG Id, some features of the syndrome seem to be 
common (Table 1). Microcephaly due to cerebral 
atrophy is mainly present at birth (Kranz et al 2007; 
Schollen et al 2005; Sun et al 2005) or develops in the 
first months of life as in the present patient (Denecke 
et al 2004, 2005; Korner et al 1999; Stibler et al 1995) 
and becomes progressively more evident in comparison 
with other growth parameters. An early-onset seizure 
disorder, often poorly controlled by antiepileptic medi-
cation, is present in nearly all patients (Denecke et al 
2004, 2005; Korner et al 1999; Kranz et al 2007; Schollen 
et al 2005). Psychomotor retardation is usually severe 
with very little progress. Only in one of the siblings 
described by Kranz and coauthors did psychomotor 
development appear to be relatively prese1ved, with 
predominant digestive symptoms (Kranz et al 2007). 
There is usually profound axial hypotonia and limb 
spasticity. Eye and vision involvement is present in all 
patients (Denecke et al 2004, 2005; Korner et al 1999; 
Kranz et al 2007; Stibler et al 1995; Schollen et al 2005; 
Sun et al 2005), often characterized by optic atrophy or 
strabismus. Club feet and contractures of digits are 
frequently seen at birth (Denecke et al 2005; Schollen 
et al 2005; Sun et al 2005). Dysmorphie features are 
usually mild at birth, but seem to become quite 
characteristic with time: the facial appearance and 
especially the profile with a broad and flat nasal bridge, 
micrognathia, thin upper lip, triangular mouth, down-
slanting palpebral fissures, strabismus, and thickened, 
large, low-implanted ears are very similar in our patient 
and in the other photographically documented patients 
(Denecke et al 2005; Kranz et al 2007; Schollen et al 
2005; Sun et al 2005); long and thin fingers seem to be 
typical (Kranz et al 2007; Sun et al 2005). Gastrointes-
tinal symptoms such as recurrent vomiting (Denecke 
et al 2004, 2005), diarrhoea and food intolerance (Kranz 
et al 2007) are described in some cases and our patient 
presented gastro-oesophageal reflux. Metabolic abnor-
malities were reported in only one patient (Sun et al 
2005), who presented with hyperinsulinaemic hypogly-
caemia. Hypoglycaemia may have occurred in other 
patients but was not documented; in our patient no 
hypoglycaemia was found and fasting insulin/glucose 
ratio was normal. Sorne aspects of the disease such as 
failure to thrive and orthopaedic complications may be 
considered secondary effects of the neurological handi-
cap rather than p1imary phenotypic features. Osteo-
penia may be linked to pathological muscular toue and 
immobilization. However, pathological fractures have 
been described in another CDG Id patient (Kranz et al 
2007) at an early age (5 years in our patient): this 
suggests that osteopenia may result from a primary 
disturbance of bone mineralization (Coman et al 2008). 
In contrast to other CDG types, CDG Id presents 
less multi-organic involvement; the phenotype is mainly 
dysmorphie and neurological. The prognosis and life-
span of CDG Id patients is difficult to assess because of 
the small number of known cases and the lack of 
detailed long-term follow-up descriptions. The clinical 
course is slowly progressive without episodes of decom-
pensation and/or acute deterioration and without 
multisystem involvement as in other inherited meta-
bolic di,;orders. Infections do not seem to trigger disease 
progression. Prognostic considerations may be very simi-
lar to those in other syndromic, non-metabolic severe 
encephalopathies, with respiratory and/or digestive com-
plications expected as in other severely hypotonie 
patients. More insights on organ-specific pathophysio-
logical mechanisms of CDG Id are probably needed 
to distinguish between primary and secondary signs of 
the disease. 
7 ~ Springer 
The patient described here is compound heterozy-
gote for two missense mutations in the ALG3 gene 
causing CDG Id. The first mutation, p.P39L, bas not 
been described so far. The second mutation, p.Rl 71 Q, 
was found at the homozygous state in the severe case 
of Sun and coauthors (Sun et al 2005); this patient 
manifested prenatal clinical signs and <lied in the 
neonatal period. Multiple sequence alignment of the 
ALG3 protein in different species showed that both 
proline 39 and arginine 171 are conserved in human, 
dog, mouse, and Drosophila (data not shown). Con-
servation through species and absence in controls 
strongly support the pathogenic role of p.P39L. The 
two missense mutations found in our patient lead to 
altered N-glycosylation, as shown by the typical accumu-
lation of truncated LLOs in our patient's fibroblasts. 
However, the presence of mature Glc3Man9GlcNAc2 
oligosaccharides reflects a residual mannosyltransferase 
activity. This residual activity might be important for 
future development of therapy for CDG Id. Indeed, 
Denecke and coauthors pointed at the possible role of 
maternai or placenta! factors responsible for a partially 
compensated N-glycosylation in CDG Id during preg-
nancy (Denecke et al 2005). Whether these factors 
compensate N-glycosylation by enhancing the residual 
enzymatic activity or through other mechanisms 
(chaperones?) remains to be clarified. 
ALG3 gene analysis allows prenatal diagnosis in 
families with CDG Id index cases. The analysis of LLO 
in chorion cells could also be a helpful tool as shown by 
Denecke and coauthors (Denecke et al 2005). Serum 
transfenfo profile is a simple screening test for CDG 
syndromes. Although multisystem involvement is usu-
ally considered a prerequisite for CDG screening, 
recent reports mention the existence of organ-specific 
CDG syndromes (Jaeken and Matthijs 2007). The pre-
sent report underlines that epileptic encephalopathy can 
be the only phenotypic manifestation of a CDG 
syndrome and suggests that transferrin screening should 
be extended to al! patients presenting an encephalopa-
thy of unknown origin. 
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Materials and Methods 
Capillary electrophoresis of serum transferrin 
To be able to have a robust capillary zone electrophoresis method for separation of the 
isoforms, a buffer system (CEofixTM CDT, Analis, Belgium) was used based on the 
patented dynamic double coating of the capillary wall. The analysis was then totally 
automated by a capillary electrophoresis instrument technique described previously 
[1, 21. 
Analysis of Lipid-linked and Protein-Linked Oligosaccharides in cultured skin 
fibroblasts 
N-glycosylation is initiated on the cytoplasmic side of the ER membrane by 
transferring two GlcNAc residues to Dolichol-P using UDP-GlcNAc as GlcNAc 
donor. The product GlcNAc2-P-P-Dol is extended by successive five different 
mannosyltransferases usmg GDP-mannose as the donor substrate. The 
oligosaccharide product Man5GlcNAc2 is translocated from the cytoplasmic side of 
the ER-membrane to the lumenal side of the organelle. This transloctaion is catalyzed 
by a flippase (Figure 1). On the lumenal side of ER, mannosyl- and 
glucosyltransferases elongate the Man5GlcNAc2 oligosaccharide to a 
Glc3Man9GlcNAc2 oligosaccharide. The Glc3Man9GlcNAc2 oligosaccharide is 
transferred to a selected asparagine residue of the nascent protein. The glycoprotein is 
transferred to the Golgi by vesicular transport, after removal of the glucose residues 
and one mannose. The alteration of the N-glycosylation pathway in CDG Id is caused 
by a defect in the assembly of the lipid-linked oligosaccharide (LLO) precursor that 
serves as a donor for the oligosaccharides transferred onto nascent glycoproteins. The 
defective enzyme is a Man5GlcNAc2-PP-dolichyl mannosyltransferase that normally 
adds mannose to Man5GlcNAc2-PP-Dol in the endoplasmic reticulum. This enzyme 
defect leads to a typical accumulation of truncated LLOs (Man5GlcNAc2) in the cells 
of CDG Id patient. To characterize this accumulation, we used fibroblasts derived 
from the patient and one control were cultured in standard medium (Dulbecco's 
modified Eagle Medium, DMEM) and labeled with 3H-mannose. Oligosaccharides 
released from dolichol were fractionated by high performance liquid chromatography 
(HPLC) technique described previously [31. 
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Molecular analysis of ALG3 gene 
RNA was extracted from control's and patient's fibroblasts according the protocol of 
the RNeasy Mini Kit (Qiagen, Hilden, Germany). 
The ALG3 cDNA was amplified in three fragments by RT-PCR (One step RT-PCR, 
Qiagen) using cDNA specific primers shown in Table 1 Primers were designed on the 
GenBank mRNA sequence (accession number NM_005787.2) and custom 
synthesized by Microsynth (Balgach, Switzerland). 
The amplified cDNA fragments were purified (Montage PCR, Millipore, USA) and 
then sequenced using fluorescence-labeled terminator reagents (Big Dye v.1.1, 
Applied Biosystems) and an automated sequencer (ABI prism 3100, Applied 
Biosystems, Poster City, CA). The same primers used for amplification were also 
used for sequence analysis. 
Genomic DNA was obtained from leucocytes, extracted according to standard 
methods. The nine exons and intron-exon boundaries of ALG3 gene were PCR 
amplified and directly sequenced. Primers (Table 1) were designed on GenBank 
sequence (accession number NT _005612.14) and they were also synthesized by 
Microsynth (Balgach, Switzerland). 
The amplified fragments were purified and then sequenced as described above for 
cDNA analysis. The same primers used for amplification were also used for sequence 
analysis. To rule out that the mutations found in our patient are a common 
polymorphism, sequence analysis of exons 1 and 4 of ALG3 gene was pe1formed in 
genomic DNA from 50 anonymous unrelated European contrais. 
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Results: 
Capillary electrophoresis of serum transferrin 
The transferrin glycoforms separation by capillary electrophoresis in our patient was 
typical of a CDG syndrome type 1 with asialo- disialo- and tetrasialotransferrin 
(Figure 2). 
Biochemical analysis of dolichol-oligosaccharides and protein-linked 
oligosaccharides. 
Pully assembled oligosaccharide with the structure Glc3Man9GlcNAc2 are 
predominantly present in the fibroblasts of healthy controls with small amounts of 
intermediate assembly products. In our patient cells, the LLOs isolated showed two 
peaks, one corresponding to the mature Glc3Man9GlcNAc2 oligosaccharide and one 
major peak corresponding to the characteristic truncated Man5-GlcNAc2 structure. 
Mutation analysis 
In the cDNA sequence analysis of ALG3 gene, two compound heterozygous 
mutations, one in exon 1 [c.116 C<T, p.P39L] and another in exon 4 [c.512 G<A, 
p.R171Q] were found in our patient. 
The mutations were confirmed in the patient's genomic DNA, sequencing of exons 1 
and 4 of ALG3gene in both parents confirmed segregation (maternai mutation: 
p.P39L, paternal mutation: p.R 171 Q). The 2 nucleotide changes found in our patient 
were not found in 100 chromosomes of anonymous unrelated European controls. 
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Primer name Oligonucleotide primer sequence 5'-<3' 
ALG3 FI [4] CACACAAGCGGCGCACCGTTAAG 
ALG3 RI GCACAAAGATGGAGTGGACACGG 
ALG3 F2 TTGCTGTGCTCTACCTGGCTAC 
ALG3 R2 AGAGGGCAAACAGCAGGAGCAG 
ALG3 F3 TTCCTGCATCGAGCCTTCCACCTG 
ALG3 R3 [4] GTAGACTCAGGTCCTGAGGGAAAG 
ALG3 ExI F [5] ACCTAAGTGTCGAAGGTTCGG 
ALG3 ExI R [5] TCTGAGATCCAGTTTGGGTCG 
ALG3 Ex2-4F[5] GTGGCAGACAAGTTCTAGACTC 
ALG3 Ex2-4 R GCAGGAAATTGGGAAGAGATGG 
ALG3 Ex5 F TGTGAGTGTAGGTCCCATCTTG 
ALG3 Ex5 R AGAAAGAGGAAGGGTGAGATGG 
ALG3 Ex6-7 F CAATGAGTAGCATGAAGGCTGG 
ALG3 Ex6-7 R ACTCTGTCAGCACCTAGAGAG 
ALG3 Ex8-9 F AGAGCCAGAGGGCTATGTGACCTA 
ALG3 R3 GTAGACTCAGGTCCTGAGGGAAAG 
Table 1: 
Primers used for cDNA analysis of ALG3 gene (NM_005787.2): Fl to R3 
Primers used for genomic DNA analysis of ALG3 gene (NT_005612.14): Exl F to R3 
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Figure 2: Capillary electrophoresis of serum transferrin. 
Fully glycosylated transferrin in a contrai patient has four sialic acids (4-sialo). CDG-ld 
patient has a typical glycosylation phenotype with increased asialo- disialo- and 
tetrasial otransferri n. 
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